KR20140077911A - 암의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제 - Google Patents

암의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제 Download PDF

Info

Publication number
KR20140077911A
KR20140077911A KR1020147009539A KR20147009539A KR20140077911A KR 20140077911 A KR20140077911 A KR 20140077911A KR 1020147009539 A KR1020147009539 A KR 1020147009539A KR 20147009539 A KR20147009539 A KR 20147009539A KR 20140077911 A KR20140077911 A KR 20140077911A
Authority
KR
South Korea
Prior art keywords
nhc
phenyl
compound
amino
alkyl
Prior art date
Application number
KR1020147009539A
Other languages
English (en)
Korean (ko)
Inventor
아서 데실리스
로드리고 루이즈 소토
개리 토마스 에몬스
조앤 라거
Original Assignee
엑셀리시스, 인코포레이티드
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑셀리시스, 인코포레이티드, 사노피 filed Critical 엑셀리시스, 인코포레이티드
Publication of KR20140077911A publication Critical patent/KR20140077911A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147009539A 2011-09-14 2012-09-14 암의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제 KR20140077911A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161534836P 2011-09-14 2011-09-14
US61/534,836 2011-09-14
US201161543529P 2011-10-05 2011-10-05
US61/543,529 2011-10-05
US201161562670P 2011-11-22 2011-11-22
US61/562,670 2011-11-22
PCT/US2012/055387 WO2013040337A1 (en) 2011-09-14 2012-09-14 Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
KR20140077911A true KR20140077911A (ko) 2014-06-24

Family

ID=46940622

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147009539A KR20140077911A (ko) 2011-09-14 2012-09-14 암의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제

Country Status (10)

Country Link
EP (1) EP2755654A1 (es)
KR (1) KR20140077911A (es)
AU (1) AU2012308414A1 (es)
BR (1) BR112014005858A2 (es)
CA (1) CA2848724A1 (es)
IL (1) IL231448A0 (es)
IN (1) IN2014CN02671A (es)
TW (1) TW201325592A (es)
UY (1) UY34339A (es)
WO (1) WO2013040337A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113754565B (zh) * 2021-11-09 2022-02-22 南京威凯尔生物医药科技有限公司 一种连续流微反应器中制备沙库巴曲中间体的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
WO2007044481A1 (en) 2005-10-07 2007-04-19 Basf Corporation Clearcoat coating composition
EP1940839B1 (en) 2005-10-07 2013-07-31 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
KR20140033237A (ko) * 2005-10-07 2014-03-17 엑셀리시스, 인코포레이티드 포스파티딜이노시톨 3-키나아제 억제제 및 이의 사용 방법
DK2139483T3 (da) * 2007-04-11 2014-01-13 Exelixis Inc Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer
WO2010146391A1 (en) * 2009-06-15 2010-12-23 Generics [Uk] Limited Regioselective synthesis of letrozole
WO2012065057A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use

Also Published As

Publication number Publication date
WO2013040337A9 (en) 2014-04-03
BR112014005858A2 (pt) 2017-06-13
WO2013040337A1 (en) 2013-03-21
AU2012308414A1 (en) 2014-05-01
IL231448A0 (en) 2014-04-30
UY34339A (es) 2013-04-30
TW201325592A (zh) 2013-07-01
EP2755654A1 (en) 2014-07-23
IN2014CN02671A (es) 2015-07-03
CA2848724A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
JP6763919B2 (ja) Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶
CN107286077B (zh) 一种选择性的c-kit激酶抑制剂
EP3601281B1 (en) CRYSTALLINE FORMS OF 4-(1-(1,1-DI(PYRIDIN-2-YL)ETHYL)-6-(3,5-DIMETHYLISOXAZOL-4-YL)-1H-
PYRROLO[3,2-B]PYRIDIN-3-YL)BENZOIC ACID THAT INHIBITS BROMODOMAIN
CN104478875B (zh) 聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
CN107427516B (zh) 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
TW201306842A (zh) 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
KR20230167053A (ko) 암 치료를 위해 prmt5 저해제를 사용하는 병용 요법
JP5901634B2 (ja) キナゾリン化合物及びその使用方法
KR102029135B1 (ko) 암 및 관련 질병 및 상태 치료용 중수소화된 화합물, 그의 조성물 및 방법
JP2021502388A (ja) Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法
KR20230167050A (ko) 암 치료를 위해 prmt5 저해제를 사용하는 병용 요법
JP2021530486A (ja) 選択的エストロゲン受容体分解剤
WO2021252678A1 (en) Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
JP2009539962A (ja) Ｐａｒｐ阻害剤としての２−オキシヘテロアリールアミド誘導体
EP2701690A1 (en) Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor
KR20140077911A (ko) 암의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제
KR101663335B1 (ko) 6-（1-메틸-1ｈ-피라졸-4-일）-2-｛3-［5-（2-모르폴린-4-일-에톡시）-피리미딘-2-일］-벤질｝-2ｈ-피리다진-3-온디히드로겐포스페이트의 신규한 다형체 및 이의 제조 방법
JPWO2008001886A1 (ja) オーロラ（Ａｕｒｏｒａ）阻害剤
JP2022542697A (ja) 癌治療用ジヌクレオチド化合物及びその医薬用途
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
CN111138426B (zh) 吲唑类激酶抑制剂及其用途
JP2024067010A (ja) 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
TW202432102A (zh) 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑
CN106608869A (zh) 一类组蛋白去甲基化酶jmjd3抑制剂及其制备方法和用途
WO2013067306A1 (en) Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid